NCAM1 and neoplasm: The analysis showed that pazopanib administration was associated with a remarkable increase of activated and cytolytic effectors, including the subset of activated T cells (CD3+PD‐1+), reported to contain tumor‐specific T cells,38 activated NK cells (CD3−CD16+CD56+PD‐1+), and cytotoxic NK cells (CD3−CD16+CD56dim) (Figure 6).39